



California State Board of Pharmacy
2720 Gateway Oaks Drive, Suite 100
Sacramento, CA 95833
Phone: (916) 518-3100 Fax: (916) 574-8618
www.pharmacy.ca.gov

Business, Consumer Services and Housing Agency
Department of Consumer Affairs
Gavin Newsom, Governor



**California State Board of Pharmacy
Department of Consumer Affairs
Enforcement and Compounding Committee Meeting Minutes**

Date: January 7, 2026

Location: OBSERVATION AND PUBLIC COMMENT IN PERSON:
California State Board of Pharmacy
2720 Gateway Oaks Drive, First Floor Hearing Room
Sacramento, CA 95833

Board of Pharmacy staff members were present at the observation and public comment location. All Committee members participated from remote locations via Webex.

PUBLIC PARTICIPATION AND COMMENT FROM
REMOTE LOCATIONS VIA WEBEX

Board Members Present:

Maria Serpa, PharmD, Licensee Member, Chair
Renee Barker, PharmD, Licensee Member, Vice Chair
Jeff Hughes, Public Member
Seung Oh, PharmD, Licensee Member
Ricardo Sanchez, Public Member
Nicole Thibeau, PharmD, Licensee Member

Staff Present:

Anne Sodergren, Executive Officer
Julie Ansel, Deputy Executive Officer
Corinne Gartner, DCA Counsel
Jennifer Robbins, DCA Regulations Counsel (Webex)
Julie McFall, Executive Specialist Manager

I. Call to Order, Establishment of Quorum, and General Announcements

Chairperson Serpa called the meeting to order at approximately 9:00 a.m. Dr. Serpa reminded everyone that the Board is a consumer protection agency charged with administering and enforcing Pharmacy Law. Department of Consumer Affairs' staff provided instructions for participating in the meeting.

Roll call was taken. The following members were present via Webex: Renee Barker, Licensee Member; Jeff Hughes, Public Member; Seung Oh, Licensee Member; Ricardo Sanchez, Public Member; Nicole Thibeau, Licensee Member; and Maria Serpa, Licensee Member. A quorum was established.

Dr. Serpa reminded Committee members to remain visible with cameras on throughout the open session of the meeting. Dr. Serpa advised if members needed to temporarily turn off their camera due to challenges with internet connectivity, they must announce the reason for their non-appearance when the camera was turned off.

II. Public Comments on Items Not on the Agenda/Agenda Items for Future Meetings

There were no public members in the Sacramento location. Members of the public participating via Webex were provided the opportunity to comment; however, no comments were made.

Chairperson Serpa noted that a written comment was submitted which was sent to the Ask Inspector team since the comment was a question and not related to agenda items for future meetings.

III. Discussion and Possible Action to Approve Minutes of the October 16, 2025 Enforcement and Compounding Committee Meeting

The draft minutes of the October 16, 2025 Enforcement and Compounding Committee meeting were presented for review and approval. Members were provided the opportunity to comment; however, no comments were made.

Motion: Approve October 16, 2025 Enforcement and Compounding Committee meeting minutes as presented.

M/S: Oh/Sanchez

There were no public members in the Sacramento location. Members of the public participating via Webex were provided the opportunity to comment; however, no comments were made.

Support: 6 Oppose: 0 Abstain: 0 Not Present: 0

Board Member	Vote
Barker	Support
Hughes	Support
Oh	Support
Sanchez	Support
Serpa	Support
Thibeau	Support

IV. Discussion and Possible Action to Make a Recommendation to the Board to Amend Business and Professions Code (BPC) Sections 4034, 4129, 4129.1, 4129.2 and 4303.1 Related to Outsourcing Facilities

Dr. Serpa recalled during the October 2025 Enforcement and Compounding Committee meeting, the Committee received an educational presentation from staff on the Board's outsourcing program. Dr. Serpa provided background on outsourcing facilities and noted the presentation is available for viewing on the Board's website.

Dr. Serpa noted that during the October meeting, members noted there may be opportunities for possible nonsubstantive changes to the statutes governing outsourcing facilities.

Dr. Serpa referred to the meeting materials, which included a copy of the proposed draft amendments. Dr. Serpa provided an overview of the proposed changes and noted she had reviewed the draft language and believed it was appropriate.

Members were provided the opportunity to comment. Members spoke in support of the changes.

There were no public members in the Sacramento location. Members of the public participating via Webex were provided the opportunity to comment; however, no comments were made.

Dr. Serpa noted that the draft language would be referred to the full Board for consideration and possible action.

V. Discussion Regarding Holding Possible Listening Session on Title 16, California Code of Regulations, Section 1707.2 Related to Duty to Consult

Dr. Serpa recalled during the October 2025 Enforcement and Compounding Committee meeting, the Committee received a presentation on the duty to consult, and the Committee expressed interest in gathering more information to assist in its evaluation of the Board's current consultation requirements and to better understand what barriers exist to pharmacist-provided consultation.

Dr. Serpa noted the Committee and the Board would be looking to the public for feedback and knowledge on opportunities to improve patient understanding of medications, reduce medication errors, and educate patients on their medications so they are taken safely and effectively. The Committee believed receiving feedback from the public regarding challenges and barriers to consultation would be vital to gain insight before any possible changes to the regulation are considered.

Dr. Serpa noted that staff were suggesting the Board hold a listening session with public participation to share opinions and insights on the duty to consult. The purpose of the listening session would be to gather feedback from the public in an open forum to ensure that diverse perspectives on consultation are considered, so that the Committee can hear concerns, challenges, and ideas related to patient consultation.

Dr. Serpa referred to the meeting materials, which included proposed questions to ask participants in a listening session.

Members were provided the opportunity to comment. Members agreed that a listening session would be valuable. Members discussed potential additional questions to ask. Members also discussed whether a survey would be more beneficial.

Members noted that patients don't always understand the value of consultation and suggested the Communication and Public Education Committee could start a campaign to educate patients about this topic.

Members continued to discuss additional questions that could be asked and suggested that multiple listening sessions could be held.

Dr. Serpa noted that as a next step, the Committee will take the item to full Board for additional feedback.

There were no public members in the Sacramento location. Members of the public participating via Webex were provided the opportunity to comment. Commenters noted a standard of care approach should also be applied to the duty to consult. A commenter also expressed concerns about how the current regulations were being enforced and encouraged the Committee and the Board to review and clarify the standards for what constitutes an appropriate declination of consultation. Another commenter felt a pharmacy technician should be able to ask simple questions to the patients and noted concerns with software which indicate the technician had provided the prescription to the pharmacist.

Members were provided the opportunity to comment having heard public comments. A member commented that conversations at the Board meeting should be robust.

VI. Discussion and Possible Action to Make a Recommendation to the Board Regarding Proposed Frequently Asked Questions Related to the Board's Regulations on Compounded Drug Preparations

Dr. Serpa reminded members that as part of the Board's licensee education efforts, the Board has a series of Frequently Asked Questions (FAQs) available on its website to assist licensees in understanding pharmacy law and regulations. The Board's updated compounding regulations for nonsterile compounding, sterile compounding, compounding of hazardous drugs, and processing of radiopharmaceuticals became effective October 1, 2025. Staff has proposed a new set of FAQs on the topic of the Board's recently approved compounding regulations.

Dr. Serpa noted the proposed FAQs are arranged into four sections covering General Compounding, Nonsterile Compounding, Sterile Compounding and Hazardous Drug Compounding. The document is intended to assist licensees with understanding the California regulations that took effect on October 1, 2025. The regulations are in addition to, not in replacement of, applicable

state and federal law and USP standards. Dr. Serpa further noted the FAQs are for informational purposes only and are not, nor are they a substitute for, legal advice.

Dr. Serpa thanked Board staff and member Renee Barker for their assistance in compiling the FAQs and noted the FAQs are intended as a dynamic document that may be updated periodically. Dr. Serpa noted she had reviewed the draft compounding FAQs as proposed and believed they are well written, comprehensive, and appropriate.

Members were provided the opportunity to comment. A member suggested that if an abbreviation such as CNSP appears in a question, that it be written out since people scan to questions and may not see the acronym defined in earlier answers. Members spoke in support of the FAQs.

Motion: Recommend approval of the proposed FAQs related to the Board's compounding regulations that took effect on October 1, 2025, consistent with the Committee's discussion and refer the proposed FAQs to the Board for approval.

M/S: Barker/Thibeau

There were no public members in the Sacramento location. Members of the public participating via Webex were provided the opportunity to comment; however, no comments were made.

Support: 6 Oppose: 0 Abstain: 0 Not Present: 0

Board Member	Vote
Barker	Support
Hughes	Support
Oh	Support
Sanchez	Support
Serpa	Support
Thibeau	Support

VII. Discussion and Possible Action to Make a Recommendation to the Board Regarding Updates to Community Pharmacy Self-Assessment/ Hospital Outpatient Pharmacy Self- Assessment

Dr. Serpa noted that historically, the Board's self-assessment requirements resided in various provisions of pharmacy law and regulations. The Board's sunset bill, Assembly Bill 1503 (Berman, Chapter 196, Statutes of 2025), which became effective on January 1, 2026, centralized the self-assessment process into statute. New BPC section 4040.6 provides that the self-assessment process shall be performed on a form approved by the Board in consultation with stakeholders and posted on its website. AB 1503 allows the Board to streamline the process of annually updating the forms and ensures consistency in the Board's approach to promoting licensee self-compliance.

Dr. Serpa further noted that as part of the current annual updates, the Board is updating the contents of the Community Pharmacy/Hospital Outpatient Pharmacy self-assessment form to reflect new laws and regulations as well as updating the format of the form. The goal of the new self-assessment form format is to be clear and concise. The Board plans to update all self-assessment forms to a similar format and each form will be discussed at future Committee meetings.

Dr. Serpa referred to the meeting materials, which include a draft of the updated Community Pharmacy/Hospital Outpatient Pharmacy self-assessment form in Attachment 4. The draft form is arranged by pharmacy law and regulation category requirements and each section references the law or regulation requirement and has a hyperlink to the specific law section referenced.

Members were provided the opportunity to comment. Members spoke in support of the draft form and appreciated the links. Members suggested providing more direction about when to use "not applicable" versus "no," and made formatting suggestions. Members recommended adding a section on how to fill out the form rather than having the header on every page, as well as adding a table of contents and a reference list of acronyms such as BPC and CCR. Members also discussed the necessity of signing and dating each page of the form.

Motion: Recommend approval of the newly developed and updated Community Pharmacy Self-Assessment/Hospital Outpatient

Pharmacy Self-Assessment form consistent with the Committee's discussion and refer the draft form to the Board for approval.

M/S: Barker/Sanchez

There were no public members in the Sacramento location. Members of the public participating via Webex were provided the opportunity to comment. The Committee heard comments from a representative of Kaiser Permanente recognizing the significant amount of work the Board had done to redesign and streamline the self-assessment form. The commenter recommended several specific changes to the questions. Another commenter expressed concern about stakeholder involvement.

Members were provided the opportunity to comment having heard public comments. Members reviewed each comment and noted the changes suggested.

Support: 6 Oppose: 0 Abstain: 0 Not Present: 0

Board Member	Vote
Barker	Support
Hughes	Support
Oh	Support
Sanchez	Support
Serpa	Support
Thibeau	Support

VIII. Discussion of Enforcement Statistics

Dr. Serpa advised the meeting materials included a summary of enforcement statistics for the first five months of fiscal year 2025/26. During the first five months of fiscal year 2025/26 the Board has initiated 1,545 complaints and closed 1,271 investigations. As of December 1, 2025, the Board has 1,784 field investigations pending. Dr. Serpa noted the meeting materials provided a breakdown of the average timeframe for the various stages of the field investigation process.

Members were provided the opportunity to comment; however, no comments were made.

There were no public members in the Sacramento location. Members of the public participating via Webex were provided the opportunity to comment; however, no comments were made.

IX. Advisement of Future Committee Meeting Dates

Dr. Serpa advised the next meeting was currently scheduled for April 16, 2026.

X. Adjournment

The meeting adjourned at 10:45 a.m.